ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.682,56
-0,45%
S&P 500
5.308,13
0,09%
Dow Jones
39.806,77
-0,49%
Euro vs US Dollar
1,08644
0,04%
Bitcoin
71.346,00
-0,14%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ATAI Life Sciences NV (ATAI)

  7. ATAI Life Sciences NV (ATAI) News

ATAI

ATAI Life Sciences NV (ATAI)

ATAI Life Sciences NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ATAI
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
15/05/202413h53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATAIATAI Life Sciences NV
15/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
15/05/202412h59GlobeNewswire Inc.atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ATAIATAI Life Sciences NV
24/04/202413h00GlobeNewswire Inc.atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
17/04/202413h00GlobeNewswire Inc.atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyNASDAQ:ATAIATAI Life Sciences NV
28/03/202412h00GlobeNewswire Inc.atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsNASDAQ:ATAIATAI Life Sciences NV
27/03/202412h00GlobeNewswire Inc.atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionNASDAQ:ATAIATAI Life Sciences NV
04/03/202414h00GlobeNewswire Inc.atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01NASDAQ:ATAIATAI Life Sciences NV
28/02/202423h00GlobeNewswire Inc.atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceNASDAQ:ATAIATAI Life Sciences NV
13/02/202422h29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATAIATAI Life Sciences NV
06/02/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
06/02/202423h00GlobeNewswire Inc.atai Life Sciences Appoints Anne Johnson as Chief Financial OfficerNASDAQ:ATAIATAI Life Sciences NV
23/01/202413h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
09/01/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
09/01/202422h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
04/01/202414h53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
04/01/202413h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
04/01/202413h00GlobeNewswire Inc.atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsNASDAQ:ATAIATAI Life Sciences NV
02/01/202414h00GlobeNewswire Inc.atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)NASDAQ:ATAIATAI Life Sciences NV
20/11/202315h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
14/11/202313h03GlobeNewswire Inc.atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ATAIATAI Life Sciences NV
13/10/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
10/10/202314h00PR Newswire (Canada)ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORTNASDAQ:ATAIATAI Life Sciences NV
06/10/202322h05GlobeNewswire Inc.atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:ATAIATAI Life Sciences NV
02/10/202322h13GlobeNewswire Inc.atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsNASDAQ:ATAIATAI Life Sciences NV
29/09/202322h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATAIATAI Life Sciences NV
14/09/202322h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATAIATAI Life Sciences NV
14/09/202314h02GlobeNewswire Inc.atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ATAIATAI Life Sciences NV
06/09/202322h01GlobeNewswire Inc.atai Life Sciences to Participate in Upcoming September Investor ConferencesNASDAQ:ATAIATAI Life Sciences NV
 Showing the most relevant articles for your search:NASDAQ:ATAI

Kürzlich von Ihnen besucht

CCOM
US500
US 500
AMEX
XLV
Health Care Select Sector
CCOM
US100
US Tech 100
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
FX
EURGBP
Euro vs Sterling
TG
ALV
Allianz
USOTC
BNPQY
BNP Paribas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
DAX
DAX
AMEX
XLE
Energy Select Sector SPDR
FX
EURUSD
Euro vs US Dollar
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten